Press Releases

Chicago Super Run Participants Walk and Run for FTD Awareness

When Chicago’s Frank Callea was diagnosed with the primary progressive aphasia form of FTD at age 54, the multi-decade Chicago Tribune technology executive vowed to make a difference, even as he stepped away from his professional life. This Saturday, he and his wife, Amy Bouschart-Callea, will join more than 40 friends, family members, fellow AFTD volunteers and AFTD staff at the Chicago Super Run 5K, running to raise FTD awareness. Click here for more information.

Hinchey Family Announces that Former Congressman Maurice D. Hinchey Has Been Diagnosed with FTD

The family of former New York Congressman Maurice D. Hinchey has announced that he has the primary progressive aphasia variant of FTD. Hinchey’s PPA symptoms began as the occasional lost word, but within a relatively short time the disease further affected his eloquent sense of language. Hinchey’s distinguished career in public service spanned 38 years in the U.S. House of Representatives and New York State Assembly. A full press release can be seen here.

Hundreds Impacted by Young-Onset Dementia to Gather in Baltimore for AFTD Conference

AFTD will hold their 2017 education conference in Baltimore, MD at the Sheraton Inner Harbor Hotel, on Friday, May 5. Each year, AFTD hosts an annual conference so that people affected by FTD can meet in person, connect and gain access to important resources and information. FTD caregivers, persons diagnosed, researchers and medical professionals all gather to make this event of significant importance for all affected by FTD. The full press release can be seen here.

AFTD Awards $2 Million to Advance Biomarkers Research Targeting Young-Onset Dementia

Doctors often rely on biomarkers – objective, easily measured biological features that indicate underlying pathology— to support accurate diagnosis and treatment efforts. Blood pressure, for example, is a widely-used biomarker for cardiovascular disease. Today, no comparable measures exist for FTD. The Association for Frontotemporal Degeneration (AFTD) aims to address these challenges with the award of $2 million to fund cutting-edge research into the discovery of FTD biomarkers.

After reviewing proposals from leading researchers worldwide, an expert panel has selected five researchers for multi-year FTD Biomarker awards. Recently released on PRNewswire, the full press release can be seen here.

The Lauder and Newhouse Foundations Announce New Initiative to Find Treatments for FTD

AFTD is excited to share that The Lauder Foundation and the Samuel I. Newhouse Foundation have each committed $5 million to create The Treat FTD Fund, which will accelerate clinical trials for FTD over the next decade. The fund, a joint program of AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF), has the potential to advance treatments for other neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s. Read the press release, and see coverage of the announcement in USA Today, Alzheimer’s News TodayNJ.Com, The Chronicle of Philanthropy, and Practical Neurology.